Zobrazeno 1 - 10
of 221
pro vyhledávání: ''
Autor:
Thomas Pilgrim, Diego López-Otero, José Luis Zamorano, James Jin, Roxana Mehran, Cathy Chen, Peter Nordbeck, Eric Boersma, Envisage-Tavi Af Investigators, Holger Thiele, Christian Hengstenberg, Rainer Hambrecht, Fayaz A. Shawl, George Dangas, Nicolas M. Van Mieghem, Luis Nombela-Franco, Kentaro Hayashida, Piera Capranzano, Anil Duggal, Yusuke Watanabe, Pascal Vranckx, Josep Rodés-Cabau, Raul Moreno, Usman Baber, Roland Veltkamp, Petra Laeis, Marco Valgimigli, Hyo-Soo Kim, Felix Meincke, Richard A. Anderson, Patrick Ohlmann, Irene Lang, Hans Lanz, Masanori Yamamoto, Helge Möllmann, Shigeru Saito, Martin Unverdorben
Publikováno v:
New England Journal of Medicine, 385(23), 2150-2160. Massachussetts Medical Society
BACKGROUND The role of direct oral anticoagulants as compared with vitamin K antagonists for atrial fibrillation after successful transcatheter aortic-valve replacement (TAVR) has not been well studied. METHODS We conducted a multicenter, prospective
Autor:
Toni K, Choueiri, Thomas, Powles, Mauricio, Burotto, Bernard, Escudier, Maria T, Bourlon, Bogdan, Zurawski, Victor M, Oyervides Juárez, James J, Hsieh, Umberto, Basso, Amishi Y, Shah, Cristina, Suárez, Alketa, Hamzaj, Jeffrey C, Goh, Carlos, Barrios, Martin, Richardet, Camillo, Porta, Rubén, Kowalyszyn, Juan P, Feregrino, Jakub, Żołnierek, David, Pook, Elizabeth R, Kessler, Yoshihiko, Tomita, Ryuichi, Mizuno, Jens, Bedke, Joshua, Zhang, Matthew A, Maurer, Burcin, Simsek, Flavia, Ejzykowicz, Gisela M, Schwab, Andrea B, Apolo, Robert J, Motzer, Suresh, Nair
Publikováno v:
New England Journal of Medicine. 384:829-841
The efficacy and safety of nivolumab plus cabozantinib as compared with those of sunitinib in the treatment of previously untreated advanced renal-cell carcinoma are not known.In this phase 3, randomized, open-label trial, we randomly assigned adults
Autor:
Gerald Watts, Farrah Deeba, David Sullivan, Paul Donald Bonnitcha, San San Min, Nimalie Jacintha Nanayakkara, Christopher Ebenbichler, Alexander Tschoner, Clemens Engler, Daniel Gaudet, Nathalie Roy, David Blackburn, Jean Bergeron, Hisee Villeneuve, Samir Saheb, Antonio Gallo, Sophia Beliard, Bertrand Dussol, Sophie Morange, Pascale Poullin, Rene Valero, Charalampos Milionis, Sebastian Filippas-Ntekouan, Eleftherios Klouras, Genovefa Kolovou, George Hatzigeorgiou, Spyridon Rammos, Paolo Rubba, Gabriella Iannuzzo, Mariko Harada-Shiba, Cheol Son, Hisashi Makino, Kiminori Hosoda, Kota Matsuki, Kyoko Kohmo, Masaki Matsubara, Masatsune Ogura, Michio Noguchio, Miki Matsuo, Ryo Koezuka, Tamiko Tamanaha, Tsutomu Tomita, Yoko Ohata, Yoshihiko Otsubo, Noriaki Koyanagi, Masaaki Kawashiri, Hayato Tada, Atsushi Nohara, Akihiro Nomura, Hirofumi Okada, Naohiko Fujii, Daisuke Hayashi, Sayoko Yonemoto, Shungo Fukuda, Koji Yanagi, Miwa Ryo, Masahiro Koseki, Makoto Nishida, Takeshi Okada, Erik Stroes, Laurens Reeskamp, Daniela Stols-Goncalves, Eva Hamulyak, Anho H Liem, Jurgen M Akkerhuis, Pieter R Nierop, Bastiaan M van Dalen, Sweder W E van de Poll, Adriana J M van Miltenburg-van Zijl, Marinus J Veerhoek, Frederick Raal, Sindeep Amrat Bhana, Olena Mitchenko, Vadym Romanov, Iryna Chulaevska, Leonid Rudenko, Olena Beregova, Igor Vakaliuk, Iryna Drapchak, Natalia Tymochko, Anna Isayeva, Olena Buriakovska, Maryna Vovchenko, Vira Tseluyko, Nataliya Matviychuk, Larysa Yakovleva, Paul Duell, Jonathan Barton Purnell, Robert Rosenson, Donald Smith, Theresa Halloran, Robert Gottlieb, Peter A McCullough, Zachary P Rosol, Andy Y Lee, Clay M Barbin, Seth J Baum, Reina Mendelson, Melissa Wright, Linda Hemphill, Akl Fahed, Traci Turner, Angela Ellard
Publikováno v:
New England journal of medicine, 383(8), 711-720. Massachussetts Medical Society
BACKGROUND: Homozygous familial hypercholesterolemia is characterized by premature cardiovascular disease caused by markedly elevated levels of low-density lipoprotein (LDL) cholesterol. This disorder is associated with genetic variants that result i
Autor:
J. S. Haw, Michael Mauer, Janet B. McGill, Jill P. Crandall, Bruce A. Perkins, Ruth S. Weinstock, Katherine R. Tuttle, Afshin Parsa, Tom Elliott, Peter Rossing, Amy B. Karger, Amisha Wallia, Cathie Spino, Mark E. Molitch, I. H. de Boer, Maryam Afkarian, David Z.I. Cherney, Sylvia E. Rosas, Irl B. Hirsch, Sarit Polsky, Allison B. Goldfine, Andrzej T. Galecki, Guillermo E. Umpierrez, Ronald J. Sigal, Marlon Pragnell, Ildiko Lingvay, M. L. Caramori, Rodica Pop-Busui, Ronnie Aronson, William N. Robiner, Chun Yi Wu, David M. Maahs, Peter A. Senior, Alessandro Doria
Publikováno v:
N Engl J Med
BACKGROUND: Higher serum urate levels are associated with an increased risk of diabetic kidney disease. Lowering of the serum urate level with allopurinol may slow the decrease in the glomerular filtration rate (GFR) in persons with type 1 diabetes a
Autor:
Axel Grothey, Sara Lonardi, Victor Sandor, Neeltje Steeghs, Rona Yaeger, Elena Elez, Yong Sang Hong, Harpreet Wasan, Christina Guo, Jan H.M. Schellens, Tae Won Kim, Eric Van Cutsem, Ashwin Gollerkeri, Tormod Kyrre Guren, Fotios Loupakis, Line Schmidt Tarpgaard, Kati Maharry, Jayesh Desai, Lisa Anderson, Sergey Orlov, Aitana Calvo Ferrándiz, Jeroen Dekervel, Michael Braun, Per Pfeiffer, Asha Krishnan, Pilar García-Alfonso, Michael D Pickard, Scott Kopetz, Janna Christy-Bittel, Hendrik Tobias Arkenau, Takayuki Yoshino, Fortunato Ciardiello, Christopher Hunt Keir, Van Morris, Josep Tabernero
Publikováno v:
Kopetz, S, Grothey, A, Yaeger, R, Van Cutsem, E, Desai, J, Yoshino, T, Wasan, H, Ciardiello, F, Loupakis, F, Hong, Y S, Steeghs, N, Guren, T K, Arkenau, H T, Garcia-Alfonso, P, Pfeiffer, P, Orlov, S, Lonardi, S, Elez, E, Kim, T W, Schellens, J H M, Guo, C, Krishnan, A, Dekervel, J, Morris, V, Ferrandiz, A C, Tarpgaard, L S, Braun, M, Gollerkeri, A, Keir, C, Maharry, K, Pickard, M, Christy-Bittel, J, Anderson, L, Sandor, V & Tabernero, J 2019, ' Encorafenib, binimetinib, and cetuximab in BRAF V600E–mutated colorectal cancer ', New England Journal of Medicine, vol. 381, no. 17, pp. 1632-1643 . https://doi.org/10.1056/NEJMoa1908075
BACKGROUND: Patients with metastatic colorectal cancer with the BRAF V600E mutation have a poor prognosis, with a median overall survival of 4 to 6 months after failure of initial therapy. Inhibition of BRAF alone has limited activity because of path
Autor:
Toni Sarapohja, M. Luz, Iris Kuss, Aramis Investigators, Christian Kappeler, Matthew R. Smith, Amir Snapir, Boris Alekseev, Neal D. Shore, Teuvo L.J. Tammela, Mindaugas Jievaltas, Sergey Polyakov, Albertas Ulys, Karim Fizazi, Egils Vjaters
Publikováno v:
New England Journal of Medicine. 380:1235-1246
Darolutamide is a structurally unique androgen-receptor antagonist that is under development for the treatment of prostate cancer. We evaluated the efficacy of darolutamide for delaying metastasis and death in men with nonmetastatic, castration-resis
Autor:
Kolb, Martin, Raghu, Ganesh, Wells, Athol U, Behr, Jürgen, Richeldi, Luca, Schinzel, Birgit, Quaresma, Manuel, Stowasser, Susanne, INSTAGE Trial Investigators, Benjamin Bondue, Bondue, Benjamin, Martinez, Fernando J
Publikováno v:
The New England journal of medicine, 379 (18
Background Nintedanib is an approved treatment for idiopathic pulmonary fibrosis (IPF). A subgroup analysis of a previously published trial suggested that sildenafil may provide benefits regarding oxygenation, gas exchange as measured by the diffusio
Autor:
Goldman, Jason D., Lye, David C.B., Hui, David S., Marks, Kristen M., Bruno, Raffaele, Montejano, Rocio, Spinner, Christoph D., Galli, Massimo, Ahn, Mi‑Young, Nahass, Ronald G., Chen, Yao-Shen, SenGupta, Devi, Hyland, Robert H., Osinusi, Anu O., Cao, Huyen, Blair, Christiana, Wei, Xuelian, Gaggar, Anuj, Brainard, Diana M., Towner, William J., Muñoz Gutiérrez, José, Mullane, Kathleen M., Marty, Francisco M., Tashima, Karen T., Diaz, George, Subramanian, Aruna, GS-US-540-5773 Investigators
Publikováno v:
Dipòsit Digital de la UB
Universidad de Barcelona
New England Journal of Medicine
The New England Journal of Medicine
Universidad de Barcelona
New England Journal of Medicine
The New England Journal of Medicine
Background Remdesivir is an RNA polymerase inhibitor with potent antiviral activity in vitro and efficacy in animal models of coronavirus disease 2019 (Covid-19). Methods We conducted a randomized, open-label, phase 3 trial involving hospitalized pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::149c6c167a6df7239d17494c5ec23e9d
http://hdl.handle.net/2445/174122
http://hdl.handle.net/2445/174122
Autor:
Lucie Blondeau, Mylène Provencher, Olivier F. Bertrand, Aldo P. Maggioni, José López-Sendón, Jean-Claude Tardif, François Roubille, Simon Kouz, Wolfgang Koenig, Marie-Pierre Dubé, Rafael Diaz, Andreas Orfanos, Reda Ibrahim, Denis Angoulvant, Petr Ostadal, Fausto J. Pinto, Jean Grégoire, Ghassan S. Kiwan, Marie-Claude Guertin, David D. Waters, Marc-André Lavoie, David Rhainds, Colin Berry, Habib Gamra, Philippe L. L’Allier
Publikováno v:
Repositório Científico de Acesso Aberto de Portugal
Repositório Científico de Acesso Aberto de Portugal (RCAAP)
instacron:RCAAP
New England Journal of Medicine
New England Journal of Medicine, 2019, ⟨10.1056/NEJMoa1912388⟩
The New England journal of medicine, vol 381, iss 26
New England Journal of Medicine, Massachusetts Medical Society, 2019, ⟨10.1056/NEJMoa1912388⟩
Repositório Científico de Acesso Aberto de Portugal (RCAAP)
instacron:RCAAP
New England Journal of Medicine
New England Journal of Medicine, 2019, ⟨10.1056/NEJMoa1912388⟩
The New England journal of medicine, vol 381, iss 26
New England Journal of Medicine, Massachusetts Medical Society, 2019, ⟨10.1056/NEJMoa1912388⟩
Copyright © 2019 Massachusetts Medical Society. All rights reserved.
Background: Experimental and clinical evidence support the role of inflammation in atherosclerosis and its complications. Colchicine is an orally administered, potent antiinfl
Background: Experimental and clinical evidence support the role of inflammation in atherosclerosis and its complications. Colchicine is an orally administered, potent antiinfl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::245444c6724cffe5dc69b81d63e21083
https://eprints.gla.ac.uk/204890/1/204890.pdf
https://eprints.gla.ac.uk/204890/1/204890.pdf
Autor:
Johannes Oldenburg, Víctor Jiménez-Yuste, Gallia G. Levy, M Elisa Mancuso, Willem Bujan, Christine L. Kempton, Elina Asikanius, Joanne I. Adamkewicz, Christophe Dhalluin, Markus Niggli, Midori Shima, Ido Paz-Priel, Michael U. Callaghan, Claude Negrier, Johnny Mahlangu, Christophe Schmitt, Rebecca Kruse-Jarres
Publikováno v:
New England Journal of Medicine. 379:811-822
Emicizumab is a bispecific monoclonal antibody that bridges activated factor IX and factor X to replace the function of missing activated factor VIII, thereby restoring hemostasis. In a phase 3, multicenter trial, we investigated its use as prophylax